Cencora, Inc. $COR Shares Sold by Great Lakes Advisors LLC

Great Lakes Advisors LLC decreased its position in shares of Cencora, Inc. (NYSE:COR) by 0.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 339,378 shares of the company’s stock after selling 3,029 shares during the quarter. Great Lakes Advisors LLC owned 0.17% of Cencora worth $114,626,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Cencora by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock worth $7,976,681,000 after purchasing an additional 221,570 shares during the period. State Street Corp grew its stake in Cencora by 9.3% in the 3rd quarter. State Street Corp now owns 9,190,316 shares of the company’s stock valued at $2,872,249,000 after acquiring an additional 782,911 shares during the period. Geode Capital Management LLC grew its stake in Cencora by 3.2% in the 4th quarter. Geode Capital Management LLC now owns 5,459,476 shares of the company’s stock valued at $1,843,268,000 after acquiring an additional 169,055 shares during the period. JPMorgan Chase & Co. grew its stake in Cencora by 6.5% in the 4th quarter. JPMorgan Chase & Co. now owns 4,982,557 shares of the company’s stock valued at $1,682,859,000 after acquiring an additional 304,760 shares during the period. Finally, Boston Partners grew its stake in Cencora by 2.0% in the 3rd quarter. Boston Partners now owns 4,509,165 shares of the company’s stock valued at $1,409,152,000 after acquiring an additional 89,506 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Trading Up 0.2%

Shares of COR stock opened at $281.88 on Friday. The stock’s fifty day moving average is $289.95 and its two-hundred day moving average is $327.96. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The firm has a market capitalization of $54.84 billion, a P/E ratio of 21.62, a PEG ratio of 1.52 and a beta of 0.59. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Research analysts expect that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were issued a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Cencora declared that its Board of Directors has authorized a share repurchase plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to reacquire up to 3.9% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on COR. William Blair began coverage on shares of Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating on the stock. Leerink Partners reissued an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Weiss Ratings cut shares of Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 22nd. Wells Fargo & Company dropped their price target on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research note on Monday, May 11th. Finally, Robert W. Baird dropped their price target on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Twelve analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $374.00.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.